Related Experiment Video

Updated: Aug 15, 2026

Isolation of Human Ventricular Cardiomyocytes from Vibratome-Cut Myocardial Slices
11:19

Isolation of Human Ventricular Cardiomyocytes from Vibratome-Cut Myocardial Slices

Published on: May 10, 2020

Potassium and magnesium depletions in congestive heart failure--pathophysiology, consequences and replenishment

Igor N Iezhitsa1

  • 1Volgograd State Medical University, Department of pharmacology. Igor_Iezhitsa@yahoo.com

Clinical Calcium
|November 8, 2005
PubMed

Insights

Potassium and magnesium deficiencies are common in congestive heart failure (CHF) and linked to complications. Restoring these essential minerals, often together, is crucial for managing CHF and its associated risks.

Area of Science:

  • Cardiology
  • Clinical Nutrition
  • Pharmacology

Background:

  • Congestive heart failure (CHF) prevalence is increasing globally.
  • Potassium (K) and magnesium (Mg) deficiencies are frequently observed in CHF patients.
  • These deficiencies are linked to increased risk factors and complications of heart failure (HF).

Purpose of the Study:

  • To highlight the significance of K and Mg restoration in CHF management.
  • To emphasize the necessity of co-supplementation for effective K repletion.
  • To discuss the therapeutic roles of Mg and K in specific CHF-related conditions.

Main Methods:

  • Review of mechanisms causing K and Mg depletion in CHF.
  • Analysis of consequences of K and Mg deficiencies.
  • Evaluation of therapeutic strategies for K and Mg restoration.

Main Results:

  • Major causes of depletion include neuroendocrine activation, digoxin, and diuretic therapy.
  • K and Mg deficiencies increase arrhythmic risk and vasoconstriction.
  • Co-supplementation of Mg and K is essential for optimal K repletion.

Conclusions:

  • Mg and K restoration is critical in CHF due to deficiency consequences.
  • Co-supplementation of Mg and K is necessary for effective K repletion.
  • Mg and K are vital for digitalis intoxication, drug-related arrhythmias, and as adjuvant therapy in diuretic-treated CHF patients.
  • Potassium-magnesium sparing diuretics offer an alternative for restoring electrolyte balance.

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.